Biological Roles of Malignant Pleural Fluid in the Carcinogenesis of Mesothelioma
Malignant pleural effusion develops when cancer causes abnormal accumulation of fluid (usually litres) in the pleural cavity between the outside of the lung and the chest wall. Most (95% of) malignant pleural mesothelioma (MPM) patients suffer from a pleural effusion.
It is commonly thought that the pleural effusion is simply a by-product of cancer involvement of the pleura. Our studies are aimed at determining why MPM stimulates the production of such large volumes of fluid, often throughout the disease course and to establish that the malignant pleural fluid produced by MPM significantly enhances tumour cell proliferation, migration and invasion.
These findings will reveal the formation of malignant effusion as part of biological programme by which MPM facilitates its own growth and spread. It will challenge the conventional belief that the malignant effusion is a by-product of pleural cancers and will have significant impact on clinical care strategies.
The Unit is also investigating the role of MCP-1 in the development of pleural effusions from a variety of etiologies using clinical and pre-clinical models.
To get involved or for more information, contact the Research Leader.
Dr Sally Lansley
Senior Research Fellow
Prof Gary Lee
MBChB, PhD, FRACP, FRCP, FCCP
Head of Pleural Medicine Group